

People

Appointments

PTC Therapeutics appoints Langdon Miller as Chief Medical Officer

PTC Therapeutics (<http://www.ptcbio.com>), a privately held biopharmaceutical company, recently announced the appointment of Langdon Miller as Chief Medical Officer. In this capacity, Miller will be responsible for establishing and managing PTC's clinical development programmes in genetic disorders, oncology and infectious diseases. He was most recently VP of Global Clinical Research in Oncology at Pharmacia Corporation.

Stuart Peltz, President and CEO of PTC, commented: 'We are thrilled to welcome Miller to our senior management team. He is a distinguished industry leader with two decades of clinical development knowledge. His experience in designing and conducting clinical trials at Pharmacia and at the National Cancer Institute will be invaluable in building PTC's clinical capabilities'.

PTC discovers and develops small molecule drugs by applying its integrated RNA biology and chemistry platforms. PTC's compounds modulate gene expression by selectively binding to either RNA targets or to proteins that interact with RNA.

AtheroGenomics promotes Martin A. Wasserman to Senior VP of Discovery Research

AtheroGenomics (<http://www.atheroGenomics.com>) has recently announced the promotion of Martin A. Wasserman to the position of Senior Vice President of Discovery Research. Since joining the company in 2001, Wasserman has been VP of Discovery Research and CSO, and his experience in the pharmaceutical field spans three decades.

The President and CEO of the company, Russell M. Medford, said of the promotion: 'Positioning Marty at the helm of our discovery research team gives us the opportunity to build on his expertise and leadership in support of our drug development efforts.'

AtheroGenomics is a pharmaceutical company focused on the discovery, development and commercialization of

novel drugs for the treatment of chronic inflammatory diseases, including heart disease (atherosclerosis), rheumatoid arthritis and asthma.

Christer de Flon appointed President and CEO of Carlsson Research

Carlsson Research AB (<http://www.carlssonresearch.com>), the Gothenberg based pharmaceutical R&D company, recently announced the appointment of Christer de Flon as President and CEO of the company.

'It is great to have Christer de Flon joining us,' said Erik Haglund, Chairman of the Board, 'He brings rich marketing and brand experiences and has broad pharmaceutical knowledge'.

A native of Sweden, de Flon held key sales and marketing positions within Hassle, Astra and Astra Zeneca between 1975 and 2001. Since then he has served as Senior Vice President and Marketing Director with Vitrolife AB.

Carlsson Research is devoted to the discovery and clinical development of new pharmacological treatment principles for psychiatric and neurological disorders. The company has created an innovative and effective system, ISP, for developing drug candidates within the CNS area.

Solexa appoints Clive G. Brown as Head of Bioinformatics

Solexa (<http://www.solexa.co.uk>), the UK-based company developing a system that will enable rapid sequencing of individual genomes, has announced the appointment of Clive G. Brown as Head of Bioinformatics. Brown was formerly a Bioinformatics consultant working at Oxford Glycosciences (OGS) where he helped to initiate, design and implement the protein atlas of the Human Genome™.

Commenting on his appointment, Brown said: 'Solexa is developing a platform that will radically improve the quality and quantity of information about genetic variation available in the areas of genetics and genomics, ranging from gene discovery through to clinical applications. The quantity of raw sequence data generated by each Solexa system will be close to that of the entire Human Genome

Project. I am delighted to be joining the Company at this exciting time.'

Nick McCooke, CEO of Solexa, said: 'Clive's appointment to the position of Head of Bioinformatics will help us expand our capabilities in this critical area, bringing us another step closer to the completion of our genome sequencing system prototype.'

Awards

Glynn Edwards and Anne Bruinvels receive 'Entrepreneur of the Year' awards

The 2003 winners of the London Biotechnology Network 'Entrepreneur of the Year' Award are Glynn Edwards, CEO of Antisoma (<http://www.antisoma.com>), which develops anticancer products, and Anne Bruinvels of Curidium (<http://www.curidium.com>), a novel drug development start-up. The event is organized by the London Biotechnology Network, which was set up by the capital's business organization, London First, and sponsored by the London Development Agency.

Edwards will receive his award for securing a major European strategic alliance with Roche (<http://www.roche.com>), which grants Roche exclusive worldwide rights to Antisoma's oncology products. This deal was negotiated and secured in 2002, which was a difficult financial year for the biotech industry. Anne Bruinvels receives her award in recognition of the risk and persistence she has shown in building up a new UK biotech venture.

Valerie Owen, Director of Healthcare at London First, said: 'These awards recognize the tremendous, innovative work of these two individuals. They are both contributing to the fast growing biotechnology sector in London, which is built on the universities' increasing sophistication in commercializing biotechnology research by forming new company spin-outs. This helps to reinforce London's position as a world-class centre of medical excellence.'

People was written by
*Steve Carney, Christopher Watson
and Hazel Winter*